Stock Analysis of Abcellera Biologics Inc (ABCL) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ABCL
Close 3.78
Change 0.080 / 2.16 %
Volume 1348.12 K
Vol Change 322419 / 31.43 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Mild Stability


Fundamental View of Abcellera Biologics Inc
PE (TTM)

-7.47

Very Poor
Price / Book

1.33

Good
Price / Sales

30.68

Very Poor
Piotroski F Score

4.0

Indecisive
Market Cap

1111.52 M

Enterprise Value

984362 K

ROA (TTM)

-13.00

Very Poor
ROE (TTM)

-12.52

Very Poor
Net Margin (TTM)

-410.47

Very Poor
Revenue

89.62 %

50391.00 K
Net Profit

181.47 %

-129141.00 K
Debt to Equity

0.0053

Excellent
Altman Z Score

2.62

Indecisive
Quick Ratio

7.32

Excellent
Cash Ratio

6.39

Excellent


Highs/Lows of Abcellera Biologics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week3.95 4.30 % 1.59 % 4.0153.66514-May-2416-May-24
Two Week3.85 1.82 % 4.60 % 4.283.66507-May-2416-May-24
One Month4.05 6.67 % 4.86 % 4.313.6223-Apr-2425-Apr-24
Three Month5.34 29.21 % 5.82 % 5.453.6220-Feb-2425-Apr-24
Six Months4.38 13.70 % 17.50 % 6.053.6208-Jan-2425-Apr-24
One year5.7 33.68 % 28.89 % 8.053.6219-Jul-2325-Apr-24
Two year7.81 51.60 % 32.16 % 14.973.6215-Nov-2225-Apr-24


Technical View of Abcellera Biologics Inc
RSI

41.64

Neutral
MACD

-0.125

Bullish
ADX

12.89

Neutral
Super Trend

4.40

Mild Bearish
Williams %R

-80.00

Mild Bullish
CCI

-87.33

Neutral


EMA 5

3.80

Mild Bearish
EMA 15

3.88

Mild Bearish
EMA 50

4.21

Strong Bearish
EMA 100

4.54

Mild Bearish
SMA 100

4.78

Mild Bearish
SMA 200

4.85

Strong Bearish
SMA 5 / 20

3.80 / 3.87

Bearish
SMA 15 / 50

3.86 / 4.25

Mild Bearish
SMA 50 / 200

4.25 / 4.85

Strong Bearish




Charts of Abcellera Biologics Inc


Returns of Abcellera Biologics Inc with Peers
Period / StockABCLELVNIMTXCOLL
1 Week-4.30%-0.377%1.60%-11.07%
1 Mth-6.67%27.39%4.14%-4.89%
3 Mth-29.21%41.81%-7.37%3.35%
6mth-13.70%128.50%27.18%34.04%
1 Year-33.68%20.13%9.91%46.20%
2 Year-51.60%25.05%69.97%117.09%
5 Years---165.75%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Abcellera Biologics Inc with Peers
Ratio / StockABCLELVNIMTXCOLL
PE-7.47-12.35-9.693781.76
P/B1.333.524.611020.52
ROA-13.00-26.89-23.657.96
ROE-12.52-28.51-47.6047.74
Debt To Equity0.00530.00140.01163.42
Revenue50391.00 K
89.62 % 		0
% 		75724.00 K
56.19 % 		546642 K
17.83 %
Net Income-129141.00 K
181.47 % 		-71584.00 K
4910.75 % 		-84078.00 K
324.12 % 		9016.00 K
136.06 %


Technicals of Abcellera Biologics Inc with Peers
Technical / StockABCLELVNIMTXCOLL-
ADX12.8928.3721.6625.52
CMF-0.2930.0041-0.357-0.129
MFI44.3152.9659.4861.55
RSI41.6463.3550.7740.26
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MAFalseTrueFalseFalse-
Price Above 200 MAFalseTrueTrueTrue-


About : Abcellera Biologics Inc

Address : 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1
Tel : 604-559-9005
URL : https://www.abcellera.com
Code : ABCL, ISIN : CA00288U1066, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 11_Dec_2020
Employee Count : 586

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.


Note : All Data Generated at the End of Trading Hours (EOD Data)